Difference between revisions of "Section 3: Results (from DOI: 10.1016/j.adro.2020.04.015) (Q11169)"
Jump to navigation
Jump to search
(Created claim: named entity (P78): durvalumab (chemical - MeSH supplementary concept) (Q11114), #quickstatements; #temporary_batch_1593384233780) |
(Removed claim: named entity (P78): COVID-19 (disease - MeSH supplementary concept) (Q7804)) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Property / named entity | |||
| - | |||
| Property / named entity: COVID-19 (disease - MeSH supplementary concept) / rank | |||
| - | |||
| Property / named entity | |||
| + | |||
| Property / named entity: Adenocarcinoma (disease - MeSH descriptor) / rank | |||
| + | Normal rank | ||
| Property / Collection or Dataset of Origin | |||
| + | |||
| Property / Collection or Dataset of Origin: Pubtator Central BioC-JSON formatted article files / rank | |||
| + | Normal rank | ||
Latest revision as of 23:50, 20 October 2020
Publication: "Need for Caution in the Diagnosis of Radiation Pneumonitis in the COVID-19 Pandemic"published as Adv Radiat Oncol; 2020 May 05; DOI: 10.1016/j.adro.2020.04.015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Section 3: Results (from DOI: 10.1016/j.adro.2020.04.015)
|
Publication: "Need for Caution in the Diagnosis of Radiation Pneumonitis in the COVID-19 Pandemic"published as Adv Radiat Oncol; 2020 May 05; DOI: 10.1016/j.adro.2020.04.015
|
Statements
0 references
0 references
0 references
0 references
0 references
0 references
0 references
